Using dexamethasone to treat severe hospital-acquired pneumonia in critically ill patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of dexamethasone combined with standard care compared to a placebo with standard care for patients suffering from severe hospital-acquired pneumonia (HAP) who exhibit a proinflammatory phenotype. It is an international phase III, double-blind, placebo-controlled, randomized trial designed to provide robust evidence on the treatment's efficacy. The study will include critically ill patients who meet specific criteria related to their pneumonia severity and inflammatory response.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Hospital-acquired pneumonia (HAP) according to European guidelines (Torres et al. Eur Respir J 2017): Association of two criteria among (body temperature \> 38°C, leukocytosis\>12000 cells per mL, leucopenia \<4000 cells per mL and purulent pulmonary secretions), appearance of a new infiltrate or change in an existing infiltrate on chest radiography, and respiratory sample (Sputum, AET, BAL, mini-BAL or blind BAL) collected for bacteriological diagnosis (results can be pending at inclusion). The diagnosis of HAP can have been made outside of ICU. Diagnosis is done at least 48 hours after hospital admission.
* HAP severity defined as a PaO2/FiO2 ratio \< 300 under mechanical ventilation.
* Biological systemic inflammatory response defined as CPR≥ 150 mg/L (15 mg/dL)\*
* Receiving curative antimicrobial therapy for the current episode of HAP pneumonia for less than 48 hours.
* Informed consent from a legal representative, or emergency procedure (when possible, according to national regulation, see below). If it is not possible to obtain the patient consent prior the inclusion (comatose patients), patient consent for the study continuation will be obtained as soon as deemed possible.
* Person insured under a health insurance scheme.
* Female of childbearing age who agree and who are able to comply with effective contraception for the 28 first days of the study.

Exclusion Criteria:

* Pregnant women (serum or urine test), breastfeeding women.
* Patient under legal protection (incl. under guardianship or trusteeship).
* Hypersensitivity to dexamethasone and hypersensitivity to all of its excipients
* Ongoing administration of glucocorticoid at the time of randomisation, such as for COVID-19 infection requiring supplemental oxygen therapy
* Severe septic shock (norepinephrine \> 0.4 microg/kg/min and serum lactate level greater than 2 mmol/L) at the time of randomisation
* Prolonged use of corticosteroids at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for \>3 weeks in the past 60 days
* Uncontrolled viral (hepatitis,herpes, zona, varicella) or systemic fungal infection
* Immunosuppression pre-existing to hospitalisation (severe lymphopenia \< 500 lymphocytes/mm3, hematologic cancer, aplasia, chemotherapy/radiotherapy for cancer within 3 months prior to the inclusion, or anti-graft rejection drug).
* Uncontrolled psychotic disorder (acute or chronical)
* Patients not expected to survive for more than 48 hours.
* Participation in another drug clinical trial :

  * testing steroids or anti-graft rejection drug or chemotherapy- radiotherapy for cancer
  * And / Or testing a drug regimen with a known interaction with dexamethasone,
  * And / Or whose implementation would alter the HAP-DEX 6-month follow-up, notably the collection of the primary outcome.
  * Situations that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study

Where it's running

• CHU Angers
  Angers, France Recruiting
• Chu Bordeaux
  Bordeaux, France Recruiting
• Chu Bordeaux
  Bordeaux, France Recruiting
• CHU Brest
  Brest, France Recruiting
• CHU Clermont - Ferrand
  Clermont-Ferrand, France Recruiting
• CHU Clermont-Ferrand
  Clermont-Ferrand, France Recruiting

Study contacts

• Principal investigator: Antoine ROQUILLY — Nantes University Hospital
• Study coordinator: Antoine ROQUILLY
• Email: antoine.roquilly@chu-nantes.fr
• Phone: +33253482876

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pneumonia After Heart Surgery: Can AI Predict It?

  This study tests whether artificial intelligence can predict hospital-acquired pneumonia after heart surgery and whether pneumonia can indicate higher risk of future heart and lung problems.

  Recruiting Tomsk National Research Medical Center of the Russian Academy of Sciences · Tomsk · NCT07745491

• Predictors and Outcomes of Ventilated Hospital-Acquired Pneumonia

  This study looks at which factors predict outcomes for patients with ventilated hospital-acquired pneumonia to help guide care.

  Recruiting Assiut University · Asyut, Asyut Governorate · NCT07667582

• Using acyclovir to treat pneumonia in ventilated patients with herpes simplex virus

  This study is testing if giving acyclovir to ICU patients on ventilators who have pneumonia and herpes simplex virus can help them survive better than those who don't receive the medication.

  Recruiting at 28 sites Phase 3 Jena University Hospital · Freiburg im Breisgau, Baden-Wurttemberg and 27 other locations · NCT06134492

• Early treatment with targeted antibiotics for severe infections using rapid diagnostics

  This study is testing if giving targeted antibiotics right away, based on quick test results, can help hospitalized patients with severe infections caused by tough-to-treat bacteria feel better faster than standard care.

  Recruiting at 21 sites Phase 4 National University of Singapore · Vellore and 20 other locations · NCT05979545

• Learning about the safety and effectiveness of Zavicefta in Korea

  This study is trying to learn how safe and effective Zavicefta is for treating serious infections in both adults and kids in Korea after it has been released for use.

  Recruiting Pfizer · Seoul, Gangnam-gu · NCT05733104

• ASK0912 versus Polymyxin B for severe hospital- or ventilator-associated pneumonia

  A phase 2 study tests two dosing regimens of ASK0912 for injection against Polymyxin B in adults with HABP or VABP to see which works best with acceptable safety.

  Recruiting Phase 2 Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Nanjing, Jiangsu · NCT07759934

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.